Name: Biogen pays $22 million to resolve drug kickback accusations
Brand: bostonherald.com
SKU: bostonherald-com-68
Availability: OnlineOnly

critic

Biogen pays $22 million to resolve drug kickback accusations

preview

By | | Boston HeraldCambridge-based Biogen — now well-known as the host of an early-pandemic superspreader event — has agreed to fork over $22 million to close the case on claims that its used two charitable funds to “game the system” and give kickbacks to people taking its multiple sclerosis drugs.U.S. Attorney Andrew Lelling’s office announced settlements on Thursday, with Biogen paying the $22 million “to resolve allegations that it violated the False Claims Act” and specialty pharmacy Advanced Care Scripts agreeing to pay $1.4 million to close the book on accusations it helped the larger company do so.“Biogen coordinated with ACS to game the system, time its payments, and direct its money to cover co-pay costs for patients using its drugs,” said First Assistant U.S. Attorney Nathaniel Mendell.The federal prosecutors say Biogen and ACS used the foundations Chronic Disease Fund and The Assistance Fund as “conduits” to pay the co-pay obligations of thousands of Medicare patients taking Avonex and Tysabri, two multiple sclerosis drugs.The feds’ “Anti-Kickback Statute” prohibits pharmaceutical companies from giving people anything — directly or indirectly — to induce Medicare patients to purchase companies’ drugs.The Chronic Disease Fund paid $2 million and The Assistance Fund paid $4 million, both last year, to resolve related allegations against them.“Biogen tried to unfairly boost its bottom line by working with Advanced Care Scripts to bill Medicare for those who were already receiving their drug for free, undermining Medicare’s co-pay structure which was set up to safeguard against inflated drug prices,” said Joseph Bonavolonta, special agent in charge of the FBI Boston Division. “Kickback schemes like this one undermine our health-care system, can compromise medical decisions, and waste taxpayer dollars.”The lawsuit stemmed from allegations from a whistleblower.Biogen is now well known for hosting a large conference downtown in the very early days of the pandemic that quickly led to 100 sick attendees, sending the company and health officials scrambling with shuttle buses to round up all the people exposed and bring them to Boston hospitals for testing. estimated some 300,000 cases can be traced back to that Feb. 26-27 conference.In all, Biogen’s two-day brainstorming session is tied to an estimated 1.6% of all coronavirus infections in the U.S., the study states.We invite you to use our commenting platform to engage in insightful conversations about issues in our community. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to us, and to disclose any information necessary to satisfy the law, regulation, or government request. We might permanently block any user who abuses these conditions.Sign up for email newslettersFollow UsMost PopularClose

By | | Boston HeraldCambridge-based Biogen — now well-known as the host of an early-pandemic superspreader event — has agreed to fork over $22 million to close the case on claims that its used two charitable funds to “game the system” and give kickbacks to people taking its multiple sclerosis drugs.U.S. Attorney Andrew Lelling’s office announced settlements on Thursday, with Biogen paying the $22 million “to resolve allegations that it violated the False Claims Act” and specialty pharmacy Advanced Care Scripts agreeing to pay $1.4 million to close the book on accusations it helped the...

public

Sean Philip Cotter

bostonherald.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Biogen pays $22 million to resolve drug kickback accusations

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS